FibroSIGHT™ Plus: Precision in Fibrosis Assessment with AI-based Analysis

Oral Presentation – Altimmune Phase 2b IMPACT Trial

Data from HistoIndex’s collaboration with Altimmune, Inc. were presented in an oral session. The presentation highlighted significant reductions in continuous fibrosis measurements using HistoIndex’s qFibrosis® AI-powered algorithm, demonstrating its ability to sensitively quantify treatment-related changes in liver fibrosis.

The findings, previously presented as a late-breaking poster (View Poster) at EASL Congress 2026, add to the growing body of evidence supporting innovative approaches to MASH treatment and fibrosis assessment.

SOLAR Conference Shark Tank

HistoIndex’s Chief Development Officer, Dr. Yukti Choudhury, Ph.D., presented the company’s latest research and technological advancements during the SOLAR Shark Tank session, showcasing the role of AI-driven quantitative pathology in advancing liver disease research and therapeutic development.

Exhibition

We appreciate the opportunity to connect with attendees at the HistoIndex exhibition booth and discuss how HistoIndex is advancing quantitative pathology for liver disease research and MASH clinical development.